Charmacy Pharmaceutical Co., Ltd. Class H

As of December 31, 2024, Charmacy Pharmaceutical Co., Ltd. Class H carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 2.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Charmacy Pharmaceutical Co., Ltd. Class H has 108.00M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Charmacy Pharmaceutical Co., Ltd. Class H maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on September 9, 2026, Charmacy Pharmaceutical Co., Ltd. Class H's stock has declined approximately 8.72% over the past 52 weeks. The 50-day moving average sits at 6.25, while the 200-day moving average is 8.35.

As of December 31, 2024, Charmacy Pharmaceutical Co., Ltd. Class H holds 599.31M in cash and equivalents against 1.81B in total debt, resulting in a net debt position of 1.16B. Total book value stands at 658.42M, with working capital of 256.89M providing operational flexibility.